Original Article

Vitrectomy combined with posterior-segment Ahmed valve implant: A case series study

M. de Frutos-Lezaun,1 I. Rodriguez-Agirretxe,a,b,* 1, F. Eder Labairu,1 C. Irigoyen1

Abstract

Purpose: To analyze the surgical outcomes and complication rates in a group of patients with refractory glaucoma who underwent simultaneous pars plana vitrectomy (PPV) and PC7 or PC8 Ahmed glaucoma valve (AGV) implantation.

Methods: Retrospective case series study of 10 eyes in 9 patients with secondary glaucoma, refractory to other treatment, who underwent 23G-PPV and implantation of PC7 or PC8 AGV between 2012 and 2014. Study variables were postoperative BCVA, IOP and the number of glaucoma medications, which were evaluated preoperatively and at 1 day, 1 week and 1, 3, 6, and 12 months after the surgical intervention. Absolute success was defined as IOP less than 21 mmHg in the absence of any medication and qualified success if medication was needed to control IOP under 21 mmHg.

Results: The average follow-up was 10.2 ± 2.89 months. Postoperative IOP levels decreased in all cases in comparison with preoperative values (p < 0.05). Absolute success rate was 60%, reaching 100% in terms of qualified success. Kaplan–Meier survival analysis showed 60% absolute success at 12 months. Changes in postoperative BCVA were not statistically significant in comparison with preoperative data. Early postoperative complications were athalamia, hyphema, and retinal detachment; late complications were pars plana clip extrusion and cystic bleb.

Conclusions: PC7 and PC8 Ahmed valve implantation via pars plana is a safe and useful option in patients with secondary refractory glaucoma who are either candidates for PPV or have been previously vitrectomized.

Keywords: Pars plana clip, Ahmed valve, PC7, Pars plana vitrectomy, Refractory glaucoma

Introduction

Glaucoma is the second leading cause of blindness, and the first cause of irreversible blindness, affecting 66.8 million people worldwide.1 Even though the frequency of glaucoma surgery has been decreasing since the 1990s2, it still offers several benefits such as a lower cost3 and more substantial4 IOP reduction with fewer fluctuations5 compared to pharmacological treatment.

Glaucoma drainage devices (GDDs), first described by Molteno in 19696, are an increasingly popular surgical option in the management of complex glaucoma.7 Due to its relatively low rate of complications, the Ahmed Glaucoma Valve (AGV) is the most frequently used valvular tube shunt.8,9
GDD’s tube placement can vary, the most frequent being the anterior chamber (AC). However, other locations such as the posterior chamber or vitreous cavity have been employed in order to reduce the associated complications, such as corneal decompensation, graft failure in keratoplasty or cataract formation.\textsuperscript{10-15}

The PC7 AGV model and its pediatric equivalent, PC8 (New World Medical, Rancho Cucamonga, CA, EEUU), have recently been developed. These devices are modified with a pars plana clip (PPC), which allows the tube to be anchored to the sclera and to be given a suitable angle, thus facilitating its placement in the posterior segment via pars plana.

The aim of this study is to analyze the surgical outcomes and complication rates in a group of glaucoma patients with high risk of surgical failure who underwent simultaneous pars plana vitrectomy (PPV) and PC7 or PC8 AGV implantation.

Methods

This is a retrospective case series study of patients presenting secondary glaucoma refractory to other treatment who underwent 23G pars plana vitrectomy and simultaneous implantation of PC7 or PC8 AGV between 2012 and 2014. The study was conducted in two surgical centers (Hospital Universitario Donostia and Instituto Clínico Quirúrgico de Oftalmología) and all surgeries were performed by the same surgeon (I.R.A). Medical records of all patients were reviewed and the following data were collected and analyzed: demographic information, type of glaucoma, number of glaucoma hypotensive medications, concurrent ocular surgeries, mean follow-up after surgery, best corrected visual acuity (BCVA), and intraocular pressure (IOP) (measured with Goldmann applanation tonometer).

Study variables were postoperative BCVA, IOP and the number of glaucoma medications. Examinations were performed preoperatively and 1 day, 1 week, 1 month, 3 months, 6 months and 1 year after surgery, except for 3 patients who received 6 months’ follow-up.

Statistical analysis

Data are displayed as mean ± standard deviation and 95% confidence intervals. BCVA was calculated using logMAR scale for statistical comparisons; visual acuity scores no better than light perception were excluded from the analysis. Comparisons of preoperative and postoperative values of BCVA, IOP, and number of medications were performed using the General Linear Model (GLM) Repeated Measures procedure. Criteria for success were defined before reviewing the data. Absolute success was achieved if IOP was less than 21 mmHg in the absence of any medication and qualified success if IOP was under 21 mmHg with medication. Kaplan Meyer’s survival curves were used to determine the surgical survival rate. P values of <0.05 were considered statistically significant. All statistics were performed using PASW 18.0 software.

Surgical technique

PC7 is a silicone Ahmed valve model with a 16 mm long and 13 mm wide drainage plate, and a 0.635 mm external diameter and 0.305 mm internal lumen tube. It has a clip that enables a 90° bending of the tube and a proper anchoring to the sclera. The PC8 pediatric model (Fig. 1A) has similar characteristics with reduced plate dimensions (10 × 9.60 mm).\textsuperscript{16}

Surgeries and additional procedures performed in each patient are listed in Table 1. All patients were operated by the same experienced surgeon under peribulbar anesthesia, with the exception of one pediatric patient who was operated under general anesthesia. The same procedure for the AGV placement was used in all patients. First, a fornix-base peritomy was performed. The valvular plate was then placed in the superior quadrant (Fig. 1B) and secured with non-absorbable 5/0 nylon sutures while the pars plana clip was sutured with a 10/0 nylon. The AGV was purged with saline solution prior to its placement.

In all cases, a simultaneous 3-port 23-G pars plana vitrectomy was performed (Fig. 1C), using one of the sclerotomies to insert the valve’s tube, which was trimmed to an appropriate length before insertion. Particular attention was paid to the vitreous base shaving in the area where the AGV tube was to be placed. Glycerin-preserved sclera was used to cover the clip in six cases; fascia lata patch graft was used in the remaining four. The conjunctiva was approximated to the limbus using 10/0 nylon sutures (Fig. 1D).

Topical antibiotics (tobramycin 4 times daily), steroids (dexamethasone phosphate 4 times daily) and cycloplegic (3 times daily) were prescribed and tapered during the 4 postoperative weeks. Fig. 2 shows postoperative image of a patient with good visualization of the tube.

Results

Ten patients were included in the study. Demographic characteristics and type of glaucoma are shown in Table 2. The mean age of the patients was 46.6 ± 26.28 years (range 4–80) and neovascular glaucoma was the most common type of glaucoma (4 cases out of 10).

The preoperative and last postoperative data (12 months) are displayed in Table 3 while mean postoperative data at every visit are displayed in Table 4. Follow-up was 12 months in 7 cases, and 6 months for the remaining patients; the average follow-up was 10.2 ± 2.89 months. The mean ± SD preoperative IOP was 37.2 ± 11.3 mmHg and the mean postoperative IOP was 16.3 ± 3.03 mmHg; the average number of medications decreased from 2.2 ± 1.48 preoperatively to 0.87 ± 1.41 on last follow-up (12 months). Postoperative IOP levels decreased in all cases in comparison with preoperative values (p < 0.05), as shown in Fig. 3. Absolute success rate was 60%, reaching 100% in terms of qualified success (glaucoma medication was necessary in 4 cases to achieve normal IOP levels). Fig. 4 represents Kaplan–Meier survival analysis of absolute success versus postoperative time showing 60% absolute success at 12 months.

Changes in postoperative BCVA were not statistically significant in comparison with preoperative BCVA, as shown in Fig. 5. Mean preoperative logMar VA declined from 1.59 ± 0.93 to 1.68 ± 1.16 after the operation. At the last follow-up, 20% of patients improved their VA, 30% stayed the same, and the VA of 50% of patients worsened. We found no postoperative loss of light perception.

Early postoperative complications were athalamia, hyphema, and retinal detachment; the last was observed in two cases (20%). One of the patients had undergone prior retinal detachment surgery and suffered a re-detachment.
4 days after the Ahmed placement. The other case was caused by a serous choroidal detachment. Late complications were pars plana clip extrusion (Fig. 6) and cystic bleb (Table 2).

**Table 1. Concurrent surgeries and additional procedures.**

| Implanted GDD | 23G PPV | Panretinal photocoagulation | Phacoemulsification of cataract | Silicone oil extraction | Intravitreal anti-VEGF injection |
|---------------|---------|-----------------------------|-------------------------------|------------------------|-----------------------------|
| 1 Ahmed PC7   | X       | X                           | X                             |                        |                            |
| 2 Ahmed PC7   | X       |                             |                               | X                      |                            |
| 3 Ahmed PC7   | X       |                             |                               |                        |                            |
| 4 Ahmed PC7   | X       |                             |                               |                        |                            |
| 5 Ahmed PC7   | X       |                             |                               |                        |                            |
| 6 Ahmed PC7   | X       | X                           |                               |                        |                            |
| 7 Ahmed PC7   | X       |                             |                               |                        |                            |
| 8 Ahmed PC8   | X       |                             |                               |                        |                            |
| 9 Ahmed PC8   | X       |                             |                               |                        |                            |
| 10 Ahmed PC7  | X       |                             |                               |                        |                            |

GDD: Glaucoma Drainage Device; 23G PPV: 23gauges pars plana vitrectomy; VEGF: Vascular endothelial Growth Factor.

**Discussion**

Since its initial description in 1995, the AGV has allowed an improvement in surgical success rates and has decreased the number of complications compared to other surgical techniques previously used in refractory glaucoma. This can be due to the equatorial placement of the implant and the trabecular bypass. However, the presence of the tube in the AC is associated with a higher risk of complications, such as endothelial decompensation and corneal graft failure. Pars plana placement of the tube has considerable advantages. Firstly, it decreases the risk of endothelial cell loss. Although the mechanism for endothelial cell loss remains unclear, intermittent tube-corneal contact, low grade inflammation and high IOP seem to be involved. Therefore, the pars plana placement of the tube is more suitable in patients with keratoplasties, endothelial disease or shallow ACs. Secondly, it constitutes a better option in eyes where the AC placement of the tube might be challenging, such as eyes with an AC intraocular lens or extensive peripheral anterior synechiae. In addition, it enables the use of the 23G sclerotomy performed for the
vitreoretinal surgery for the insertion of the tube. Finally, the clip can be easily removed and the tube placed in the AC if any complication occurs.

The disadvantages of this technique include the difficulty visualizing the tube by anterior segment biomicroscopy, the possible tube obstruction caused by vitreous incarceration and potential posterior segment complications.

Several studies have shown the effectiveness of pars plana placement of Ahmed valve. However, only few studies have analyzed the efficacy and safety of the PC7 model. In the present study, the absolute success rate was 60% at last follow-up, reaching 100% in terms of qualified success. These results are comparable to those in previous reports. Diaz-Llopis et al. achieved absolute success rates of 70% (100% qualified success) and Dada et al. reported absolute success rates of 54% (81% qualified success), both at 12 months. There are two studies where the outcomes after PC7 pars plana placement versus FP7 AC placement are compared. The absolute and qualified success rates reported by Perihar et al. at 24 months were 28% and 72%, respectively. Maris et al. have reported 90% and 74.3% success rates at 12 and 24 months, respectively.

Nevertheless, direct comparison between these studies is difficult due to variable success criteria, different follow-up times and heterogeneous patient population. For instance,

Table 2. Demographic characteristics and postoperative complications.

| Cases | Glaucoma Diagnosis       | Eye | Age | Complications          |
|-------|--------------------------|-----|-----|------------------------|
| 1     | Neovascular              | OD  | 68  | Hyphema                |
| 2     | Neovascular              | OS  | 67  | Cystic bleb            |
| 3     | Secondary to silicon oil injection | OS | 46  | Retinal detachment     |
| 4     | Inflammatory             | OD  | 51  | Cystic bleb            |
| 5     | Traumatic                | OD  | 34  | Clip extrusion         |
| 6     | Neovascular              | OD  | 67  | Athalamia              |
| 7     | Congenital               | OD  | 4   | Clip extrusion         |
| 8     | Congenital               | OS  | 4   |                        |
| 9     | Traumatic                | OS  | 45  |                        |
| 10    | Neovascular              | OS  | 80  |                       |

Table 3. Preoperative and postoperative data (12-month follow-up).

| Preoperative data BCVA (Snellen) | IOP (mmHg) | Number of medications | Postoperative data (12 month follow-up) BCVA (Snellen) | IOP (mmHg) | Number of medications |
|----------------------------------|------------|-----------------------|--------------------------------------------------------|------------|-----------------------|
| 0.7                              | 24         | 3                     | 0.5                                                   | 21         | 2                     |
| 0.05                             | 50         | 2                     | 0.01                                                  | 20         | 3                     |
| 0.001                            | 21         | 4                     | 0.001                                                 | 19         | 2                     |
| 0.001                            | 34         | 3                     | 0.01                                                  | 19         | 0                     |
| 0.01                             | 40         | 2                     | 0.05                                                  | 13*        | 2                     |
| LP                               | 50         | 4                     | LP                                                    | 19*        | 0                     |
| 0.1                              | 35         | 0                     | 0.1                                                   | 18         | 0                     |
| 0.1                              | 36         | 0                     | 0.1                                                   | 16         | 0                     |
| 0.01                             | 28         | 3                     | 0.001                                                 | 14         | 0                     |
| 0.16                             | 54         | 1                     | 0.01                                                  | 17*        | 0                     |

* IOP at 6 month follow-up.

Table 4. Mean preoperative and postoperative data at every examination.

|                        | Preoperative | 1 day | 1 week | 1 month | 3 months | 6 months | 12 months |
|------------------------|--------------|-------|--------|---------|----------|----------|-----------|
| IOP (mmHg)             | 37.2 ± 11.33 | 12.1 ± 8.53 | 13.1 ± 4.81 | 19 ± 7.21 | 16.2 ± 5.22 | 19 ± 6.93 | 18.14 ± 2.41 |
| BCVA (logMar)          | 1.6 ± 0.93   | 1.6 ± 0.79  | 1.3 ± 0.55 | 1.5 ± 0.82 | 1.2 ± 0.62 | 1.6 ± 0.84 | 1.7 ± 1.16  |
| No. of Medication      | 2.2 ± 1.48   | 0.0 ± 0.0   | 0.5 ± 1.08 | 0.6 ± 1.35 | 0.9 ± 1.52 | 1.2 ± 1.49 | 0.87 ± 1.41  |
| Relative Success (%)   | 80.00        | 90.00      | 70       | 80.00    | 70.00     | 50.00     | 60         |
| Absolute Success (%)   | 80.00        | 80         | 60       | 60.00    | 50.00     | 60        |
in the study conducted by Maris, the success criterion was IOP between 5 and 21 mmHg with or without additional medications, whereas Diaz-Llopis considered the intervention successful if IOP was less than 21 mmHg without any glaucoma medication. Success criterion for Dada et al. was similar to ours, except for a lower IOP threshold (18 mmHg). Regarding the type of glaucoma, Maris et al. reported a 25.8% rate of primary open-angle glaucomas,
whereas Parihar et al. excluded patients with neovascular glaucoma or retinal diseases. Diaz-Llopis and Dada analyzed refractory secondary glaucomas, similar to the cases in our study. All studies had a 12 month follow up period except two: one conducted by Parihar with a 24 month follow up and another by Maris with a mean follow-up of 20.9 months.

Other models of AGV and other GDDs have been implanted in the posterior segment with successful outcomes, mainly Baerveldt implants and less frequently Molteno and Krupin drainage devices. In terms of IOP levels, our surgical outcomes are similar to those reported by other authors using pars plana placement of AGV (72.2–100% in terms of qualified success) and other GDDs (61.1–100%). Finally, we achieved better success rates than those reported in Ahmed versus Baerveldt (AVB) and Ahmed Baerveldt Comparison (ABC) studies, where the results of two GGDs placed in the anterior chamber are compared.

The effect of the tube position on the IOP reduction remains unclear. The two studies comparing the anterior versus posterior segment placements of the tube have not found statistically significant differences between both groups in terms of IOP control, suggesting that GDDs with the same structure and filtration capacity should give similar results. Whether this clip affects the draining capacity by ensuring a stable anchorage at a 90° angle thereby decreasing the tube obstruction rates is still uncertain. Schlote was the first to share the results of using the PPC with PS2 Ahmed Valve (polypropylene PC7 equivalent), achieving 64% absolute success rate without any tube obstruction. The tube obstruction rate in our study (1 case – 10%) is comparable to those with AGV including the PPC (12% reported by Parihar, 12.9% by Maris, 10% by Diaz-Llopis, 3% by Chihara and 0% by Dada). Similar devices have been employed previously with this purpose, such as the Hoffman’s elbow with Baerveldt GDD employed by Lutrull et al., with 90–95% success rates and 2% cases of tube incarceration. Regarding the studies analyzing surgical outcomes of the pars plana placement of AGV or other GDDs without employing a clip, tube blockage rates vary from 0% to 25%. Further studies with bigger samples employing GDDs with or without PPC should be conducted in order to find out whether a firm anchorage of the tube at a 90° angle can improve IOP control and decrease the rates of tube obstruction.

Visual acuity after glaucoma surgery can vary depending on the severity of glaucoma, surgical complications and other
ocular comorbidities. In addition, the different preoperative stage of the glaucomas among studies makes difficult the comparison between them. In our study most of the advanced refractory glaucomas with other severe ocular conditions carried a poor VA prognosis. Half of the patients stabilized or improved their VA at last follow-up. Different VA improvement rates have been reported with pars plana placement of AGV: Maris32 (90.3%), Parihar37 (56%), Lieberman33 (52%), Seo35 (100%), Jeong36 (100%), Schlotz36 (27.7%), Faghihi37 (77.7% improved or remained unchanged), Wallsh33 (66.7%). VA improvement outcomes with other GDDs range from 22% to 77.8%.12,18,22,27,28–40,42

No intraoperative complications were registered in the present study. The most frequent postoperative complications were retinal detachment (20%), cystic bleb (20%), and pars plana clip extrusion (20%). The two patients with cystic bleb presented an IOP increase that returned to normal levels after needling and 5-fluorouracil injection of the bleb. It has been suggested that the pars plana clip might decrease the incidence of tube extrusion as it provides stable anchorage of the tube to the sclera.30 However, despite covering the clip with fascia lata or scleral patch, conjunctival erosion and clip extrusion can occur as a result of clip-conjunctiva contact, as happened in two of our cases. We report two major posterior segment complications. A patient who had been operated three times for recurrent retinal detachment suffered a re-detachment 4 days after AGV implantation and silicone oil removal surgery. The other case of retinal detachment was caused by a serous choroidal detachment associated with blockage of the tube with vitreous remnants. This patient required two more retinal detachment surgeries and the replacement of the tube in the posterior chamber. Vitreous incarceration might have been avoided by employing triamcinolone during vitrectomy, as suggested by Dada et al.31 It is difficult to elucidate, though, if the retinal detachments observed in our study are related to the PPV and posterior placement of the tube or to the underlying retinal disease. Posterior segment complications after GDD implantation have been reported both with AC and posterior segment placements.8,43 These complications range from 2.5% to 32% after PP placement of AGV tube.23–26,29–31,34–37 The frequency and severity of complications in our study were not superior to other studies of AGV placement in the posterior segment.23–26,29–31,34–37

The Ahmed valve and other GDDs have also been proved valid and effective options in the management of pediatric glaucoma, both with AC and posterior segment placement of the tube.44–52 We are aware that data extrapolation from our two cases of PC8 model implantation is not possible. However, to our knowledge, outcomes after using this pediatric model have not been previously reported.

Limitations of our study include its retrospective, non-comparative and non-randomized design, the small sample size, variable severity of diseases, and the heterogeneous follow-up times. Prospective studies with larger sample size are needed comparing surgical outcomes after Ahmed AC vs posterior segment implantation in order to provide more meaningful long-term follow-up results. Our results in terms of efficacy and safety are consistent with those in previous reports. In conclusion, Ahmed valve implantation via pars plana can be a safe and useful option in patients with refractory glaucoma and high risk of surgical failure.

Conflict of interest

The authors declared that there is no conflict of interest.

References

1. Quigley HA. The number of persons with glaucoma worldwide. Br J Ophthalmol 1996;80:389–93.
2. Whittaker KW, Gillow JT, Cumiffe IA. Is the role of trabeculectomy in glaucoma management changing? Eye 2001;15:449–52.
3. Lindblom B, Nordmann JP, Sellem E, Chen E, Gold R, Polland W, et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 2006;84:74–83.
4. Lichter PR, Musch DC, Gillespie BW, Guire KE, Jenz NK, Wren PA, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943–53.
5. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651–6.
6. Molteno AC. New implant for drainage. Animal trial. Br J Ophthalmol 1995;69:161–8.
7. Ramulu PY, Corcoran KJ, Corcoran SL, Robin AL. Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004. Ophthalmology 2007;114:2265–70.
8. Barton K, Feuer WJ, Budenz DL, Schiffman J, Costa VP, Godfrey DG, Ahmed Baerveldt Comparison Study Group, et al. Three-year treatment outcomes in the Ahmed baerveldt comparison study. Ophthalmology 2014;121:1547–57.
9. Chrestakis PG, Tsai JC, Kalenak JW, Zurakowski D, Cantor LB, Kammer JA, et al. The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology 2013;120:2232–40.
10. Hill RA, Heuer DK, Baerveldt G, Minckler DS, Martone JS. Molteno implantation for glaucoma in young patients. Ophthalmology 1991;98:1042–6.
11. Lim KS, Allan BD, Lloyd AW, Maier A, Khaw PT. Glaucoma drainage devices: past, present and future review. Br J Ophthalmol 1999;83:1083–9.
12. Joos KM, Lavina AM, Tawansy KA, Agarwal A. Posterior repositioning of glaucoma implants for anterior segment complications. Ophthalmology 2001;108:279–84.
13. Nguyen QH. Avoiding and managing complications of glaucoma drainage implants review. Curr Opin Ophthalmol 2004;15:147–55.
14. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DLTube versus Trabeculotomy Study Group. Treatment outcomes in the tube versus trabeculotomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012;153:789–803.
15. Gedde SJ, Singh K, Schiffman JC, Feuer WJ. The Tube Versus Trabeculotomy Study: interpretation of results and application to clinical practice. Curr Opin Ophthalmol 2012;23:118–26.
16. Bhata LS, Chen TC. New Ahmed valve designs. Int Ophthalmol Clin 2004;44:123–38.
17. Coleman AL, Hill R, Wilson MR, Choppin N, Kotas-Neumann R, Tam M, et al. Initial clinical experience with the Ahmed Glaucoma Valve implant. Am J Ophthalmol 1995;120:23–31.
18. Ritterband DC, Shapiro D, Trubnik V, Marmor M, Meskin S, Seedor J, Cornea Glaucoma Implant Study Group (COGIS), et al. Penetrating keratoplasty with pars plana glaucoma drainage devices. Cornea 2007;26:1060–6.
19. Sherwood MB, Smith MF, Driebe Jr WT, Stern GA, Beneke JA, Zam ZS. Drainage tube implants in the treatment of glaucoma following penetrating keratoplasty. Ophthalmic Surg 1993;24:185–9.
20. Arrayoave PC, Scott IU, Fantes FE, Feuer WJ, Murray TG. Corneal graft survival and intraocular pressure control after penetrating keratoplasty and glaucoma drainage device implantation. Ophthalmology 2001;108:1978–85.
21. Kwon YH, Taylor JM, Hong S, Honkanen RA, Zimmerman MB, Alward WL, et al. Long-term findings of eyes with penetrating keratoplasty and glaucoma drainage tube implant. Ophthalmology 2001;108:272–8.
22. Wittmer MT, Tiedeman JS, Olaskovsky LA, Conaway MR, Prum BE. Long term intraocular pressure control and corneal graft survival in
Vitrectomy combined with posterior-segment Ahmed valve implant

eyes with a pars plana Baerveldt implant and corneal transplant. J Glaucoma 2010;19:124–31.
23. Lieberman RA, Maris Jr PJ, Monroe HM, Al-Aswad LA, Bansal R, Lopez R, et al. Corneal graft survival and intraocular pressure control in coexisting penetrating keratoplasty and pars plana Ahmed Glaucoma Valves. Cornea 2012;31:350–6.
24. Panhar JK, Jain VK, Kaushik J, Mishra A. Pars plana-modified versus conventional Ahmed glaucoma valve in patients undergoing penetrating keratoplasty: a prospective comparative randomized study. Curr Eye Res 2016;27:1–7.
25. Seo JW, Lee JY, Nam DH, Lee DY. Comparison of the changes in corneal endothelial cells after pars plana and anterior chamber Ahmed valve implant. J Ophthalmol 2015;2015:48632.
26. Chihara E, Umemoto M, Tanito M. Preservation of corneal endothelium after pars plana tube insertion of the Ahmed glaucoma valve. Jpn J Ophthalmol 2012;56:119–27.
27. Sidoti PA, Mosny AY, Ritterband DC, Seedor JA. Pars plana tube insertion of glaucoma drainage implants and penetrating keratoplasty in coexisting glaucoma and corneal disease. Ophthalmology 2001;108:1050–8.
28. Lee EK, Yun YJ, Lee JE, Yim JH, Kim CS. Changes in corneal endothelial cells after Ahmed glaucoma valve implantation: 2-year follow-up. Am J Ophthalmol 2009;148:361.
29. Maris Jr PJ, Tsai JC, Khatib N, Bansal R, Al-Aswad LA. Clinical outcomes of Ahmed Glaucoma valve in posterior segment versus anterior chamber. J Glaucoma 2013;22:183–9.
30. Díaz-Llopis M, Salom D, García-Delpech S, Udaondo P, Millán JM, Arevalo JF. Efficacy and safety of the pars plana clip in the Ahmed valve device inserted via the pars plana in patients with refractory glaucoma. Clin Ophthalmol 2010;4:411–6.
31. Dada T, Bhartiya S, Vanathi M, Panda A. Pars plana Ahmed glaucoma valve implantation with triamcinolone-assisted vitrectomy in refractory glaucomas. Indian J Ophthalmol 2010;58:440–2.
32. Suárez-Fernández MJ, Gutiérrez-Díaz E, Julve San Martin A, Fernández-Reyes MF, Mencía-Gutiérrez E. Simultaneous pars plana vitrectomy and glaucoma drainage device implant. Arch Soc Esp Oftalmol 2010;85:97–102.
33. Rososinski A, Wechsler D, Grigg J. Retrospective review of pars plana versus anterior chamber placement of baerveldt glaucoma drainage device. J Glaucoma 2015;24:95–9.
34. Wallsh JO, Gallemore RP, Taban M, Hu C, Sharareh B. Pars plana Ahmed valve and vitrectomy in patients with glaucoma associated with posterior segment disease. Retina 2013;33:2059–68.
35. Jeong HS, Nam DH, Paik HJ, Lee DY. Pars plana Ahmed Implantation Combine with 23-gauge vitrectomy for refractory neovascular glaucoma in diabetic retinopathy. Korean. J Ophthalmol 2012;26:92–6.
36. Schlote T, Ziemssen F, Bartz-Schmutter. Pars-plana modified Ahmed Galucoma Valve for treatment of refractory glaucoma: a pilot study. Graefes Arch Clin Exp Ophthalmol 2006;244:336.
37. Faghihi H, Hajizadeh F, Mohammadi SF, Kadkhoda A, Peyman GA, Riazi-Esfahani M. Pars plana Ahmed valve implant and vitrectomy in the management of neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2007;38:292–300.
38. Luttrull JK, Avery RL, Baerveldt G, Easley KA. Initial experience with pneumatically stented baerveldt implant modified for pars plana insertion for complicated glaucoma. Ophthalmology 2000;107:143–9.
39. Lloyd MA, Heuer DK, Baerveldt G, Minkler DS, Martone JF, Lean JS, et al. Combined Molteno implantation and pars plana vitrectomy for neovascular glaucomas. Ophthalmology 1991;98:1401–5.
40. De Guzman MH, Valencia A, Farinelli AC. Pars plana insertion of glaucoma drainage devices for refractory glaucoma. Clin Exp Ophthalmol 2006;34:102–7.
41. Varma R, Heuer DK, Lundy DC, Baerveldt G, Lee P, Minkler DS. Pars plana Baerveldt tube insertion with vitrectomy in glaucomas associated with pseudophakia and aphakia. Am J Ophthalmol 1995;119:401–7.
42. Kolomeyer AM, Seery CW, Emami-Naeimi P, Zarbin MA, Fechtner N, Bhagat N. Combined pars plana vitrectomy and pars plana baerveldt tube placement in eyes with neovascular glaucoma. Retina 2015;35:17–28.
43. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Tube Versus Trabecelectomy Study Group. Postoperative complications in the Tube Versus Trabecelectomy (TVT) study during five years of follow-up. Am J Ophthalmol 2012;153:804–14.
44. Chen A, Yu F, Law SK, Giaconi JA, Coleman AL, Caprioli J. Valved glaucoma drainage devices in pediatric glaucoma: retrospective long-term outcomes. JAMA Ophthalmol 2015;133:1030–5.
45. Balekudaru S, Vadalkar J, George R, Vijaya L. The use of Ahmed glaucoma valve in the management of pediatric glaucoma. JAAPOS 2014;18:351–6.
46. Mandalos A, Tailor R, Parmar T, Sung V. The long-term outcomes of glaucoma drainage device in pediatric glaucoma. J Glaucoma 2014;14.
47. Al-Mobarak F, Khan AO. Two-year survival of Ahmed valve implantation in the first 2 years of life with and without intraoperative mitomycin-C. Ophthalmology 2009;116:1862–5.
48. Beck AD, Freedman S, Kammer J, Jin J. Aqueous shunt devices compared with trabeculectomy with Mitomycin-C for children in the first two years of life. Am J Ophthalmol 2003;136:994–1000.
49. Djideyre MR, Peralta Calvo J, Abelaira Gomez J. Clinical evaluation and risk factors of time to failure of Ahmed Glaucoma Valve implant in pediatric patients. Ophthalmology 2001;108:614–20.
50. El Sayed Y, Awadein A. Polypropylene vs silicone Ahmed valve with adjunctive mitomycin C in paediatric age group: a prospective controlled study. Eye (Lond) 2013;27:728–34.
51. Morad Y, Donaldson CE, Kim YM, Abdollel M, Levin AV. The Ahmed drainage implant in the treatment of pediatric glaucoma. Am J Ophthalmol 2003;135:821–9.
52. Alvis-Donado O, Gil-Carrasco F, Romero-Ojijada R, Thomas R. Evaluation of Ahmed glaucoma valve implantation through a needle-generated scleral tunnel in Mexican children with glaucoma. Indian J Ophthalmol 2010;58:365–73.